OneSkin, a biotech-driven skin longevity brand, has secured $20 million in Series A funding from Prelude Growth Partners. Unlike typical funding rounds, Prelude Growth initiated the investment, enabling OneSkin to bring on a growth-focused partner as it scales. The backing highlights growing interest in skin longevity and OneSkin’s leadership in this space.
Founded by female PhD scientists, OneSkin focuses on “skinspan,” using science to target aging at the cellular level. Their proprietary peptide OS-01 aims to reduce senescent cells, which contribute to signs of aging. Products like OS-01 FACE, BODY, EYE, LIP, and HAIR have gained traction with consumers and celebrities alike.
Prelude Growth Partners is recognized for supporting high-growth, founder-led brands, especially those led by women, across various consumer sectors. Previous OneSkin investors include Selva Ventures, Unilever Ventures, and others.
KEY QUOTES:
“We’re incredibly proud to welcome Prelude Growth Partners to the OneSkin family. Their team’s expertise in building modern consumer brands and their enthusiasm for our science-driven approach made this a natural fit. We weren’t looking for new capital — but their passion and belief in our vision made this an opportunity to expand our resources and work alongside people we deeply admire. We got ourselves a dream team!”
Carolina Reis Oliveira, PhD, Co-Founder and CEO of OneSkin
“OneSkin’s cutting edge science, novel proprietary technology, leadership in skin longevity, and compelling brand are truly unique in the category. We are extremely proud to have the opportunity to partner with Carolina, Alessandra and the team at OneSkin to support them in creating an iconic, powerhouse brand of the future.”
Alicia Sontag, Co-Founder and Managing Partner of Prelude Growth
